We found that the combined treatment with metformin and 2DG had a favorable effect on potential anti-tumor immunity by causing deglycosylation and reduced expression of PD-L1, a key immune checkpoint protein, in MDA-MB-231 cells. The gene discussed is CD274; the disease is neoplasm.